All In Biotech

Drug Trial Radar · NCT01292187

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture

Last checked: Nov 20, 2026Latest source record: Sep 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

Jan 2011

Primary completion

May 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Tarsa Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture. The secondary purpose of this study was to determine if there is any food effect by comparing the efficacy and safety of oral calcitonin tablets administered at dinner or at bedtime.

Conditions

  • Osteopenia

Interventions

  • Oral calcitonin at dinnertimeDrug

    Oral calcitonin at dinnertime.

  • Oral placebo at dinnertimeDrug

    Oral placebo at dinnertime.

  • Oral calcitonin at bedtimeDrug

    Oral calcitonin at bedtime

  • Oral placebo at bedtimeDrug

    Oral placebo at bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline to Week 54 of Lumbar Spine Bone Mineral Density of Active Compared to Placebo.Time frame: Baseline, Week 54

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida

  • Bethesda Health Research

    Bethesda, Maryland

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • Michigan Bone and Mineral Clinic

    Detroit, Michigan

  • The Osteoporosis Center at St. Luke's Hospital

    Chesterfield, Missouri

  • Comprehensive Clinical Research

    Berlin, New Jersey

  • University of Pittsburgh - Department of Neurology

    Pittsburgh, Pennsylvania

  • Puget Sound Osteoporosis Center

    Seattle, Washington

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.